We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Noscapine Slows Growth and Spread of Prostate Cancer

By LabMedica International staff writers
Posted on 31 Mar 2010
Print article
Noscapine, a nonaddictive derivative of opium commonly used as an additive in cough medicines, has been shown to be effective in limiting the growth and spread of prostate cancer.

A cooperative effort united investigators from the Prostate Cancer Research and Education Foundation (PCREF; San Diego, CA, USA), the University of California, San Diego (UCSD; USA), and the MedInsight Research Institute (Baltimore, MD, USA). They worked with a model comprising nude mice that were injected with human prostate cancer cells.

In the study, the mice received oral noscapine or diluent (control) for 56 days, beginning seven days after inoculation with PC3 human prostate cancer cells; or noscapine for 70 days, beginning seven days before inoculation with the cancer cells.

Findings were published in the February 2010 issue of the journal Anticancer Research. They showed that pretreating the mice with noscapine before injecting them with prostate cancer cells resulted in the tumor growth rate being two-thirds smaller in the noscapine group. Furthermore, lung metastasis rates were 80% less in the mice pretreated with noscapine, and the noscapine group suffered no cancer-related weight loss – compared with significant weight loss in the non-noscapine group. Overall, pretreatment with noscapine gave anticancer benefits similar to those seen for treatment that was given after injection of cancer cells. In both cases, there were no signs of toxicity to normal cells or tissues.

"Based on our research so far, we believe that noscapine could be a very promising treatment to prevent recurrence in such cases due to its excellent safety record and oral bioavailability,” said first author Dr. Israel Barken, medical director of the PCREF. "PCREF is now seeking sponsorship for clinical data collection in postsurgery patients who are at high-risk of recurrence for their prostate cancer.”

Senior author Dr. Moshe Rogosnitzky, director of research at the MedInsight Research Institute, said, "It is MedInsight's belief that many effective treatments for this and other diseases can be selected from the vast armory of existing off-patent and unpromoted drugs. The results of this study, once confirmed in a clinical trial, are an example where we may yet again have an agent that not only has an envious safety record, but is already available for use today.”

Related Links:
Prostate Cancer Research and Education Foundation
University of California, San Diego
MedInsight Research Institute


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Karius Focus BAL is designed to quickly identify the etiology of lung infections and improve diagnostic yield over standard of care testing (Photo courtesy of Karius)

Microbial Cell-Free DNA Test Accurately Identifies Pathogens Causing Pneumonia and Other Lung Infections

Bronchoalveolar lavage (BAL) is a commonly used procedure for diagnosing lung infections, especially in immunocompromised patients. However, standard tests often fail to pinpoint the exact pathogen, leading... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.